Case Report ARTICLE
Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-c prodrug (Promitil): mechanistic basis and preliminary clinical experience
- 1Shaare Zedek Medical Center, Israel
- 2Hadassah Medical Center, Israel
- 3Assuta Medical Center, Israel
- 4Lipomedix Pharmaceuticals Ltd., Israel
- 5University of North Carolina at Chapel Hill, United States
- 6Hebrew University of Jerusalem, Israel
Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.
Keywords: colorectal cancer, Oligometastases, Liposomes, Mitomycin-C, prodrug, Radiotherapy, radiosensitizer
Received: 05 Sep 2018;
Accepted: 05 Nov 2018.
Edited by:Michael T. Milano, University of Rochester, United States
Reviewed by:Eric C. Ko, Weill Cornell Medicine, Cornell University, United States
Ima Paydar, Hospital of the University of Pennsylvania, United States
Copyright: © 2018 Tahover, Bar-Shalom, Sapir, Pfeffer, Nemirovsky, Turner, Gips, Ohana, Corn, Wang and Gabizon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Alberto Gabizon, Shaare Zedek Medical Center, Jerusalem, Israel, firstname.lastname@example.org